The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Specialty Chemicals grew 38% YoY for FY23
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Subscribe To Our Newsletter & Stay Updated
